AER 1449672, is a spontaneous case, received on 12/Aug/2014 from a physician via company representative and 
concerns a patient with unspecified demographics who developed Progressive multifocal leukoencephalopathy 
when was treated with rituximab (Mabthera).
No medical history, concurrent illnesses, concomitant medications or past drugs were reported.
On an unspecified date, the patient started with rituximab (route, dose, form and frequency not provided) for 
unknown indication. Later the patient developed progressive multifocal leukoencephalopathy.
At the time of this report, the outcome of progressive multifocal leukoencephalopathy was not reported and there 
was insufficient information about the therapy ongoing status with rituximab.
The reporter did not provide the causality of progressive multifocal leukoencephalopathy to rituximab.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 213 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The company assessed progressive multifocal leukoencephalopathy as medically significant event. 
The physician declinded to report any further information. 
No further information was provided.